Invention Grant
- Patent Title: Fecal microbiota composition for use in reducing treatment-induced inflammation
-
Application No.: US17261532Application Date: 2019-07-19
-
Publication No.: US12076350B2Publication Date: 2024-09-03
- Inventor: Emilie Plantamura , Cyrielle Gasc , Benoît Levast , Lilia Boucinha , Corentin Le Camus , Carole Schwintner , Hervé Affagard
- Applicant: MaaT PHARMA
- Applicant Address: FR Lyons
- Assignee: MaaT PHARMA
- Current Assignee: MaaT PHARMA
- Current Assignee Address: FR Lyons
- Agency: ARENTFOX SCHIFF LLP
- Priority: EP 305997 2018.07.20 WO TFR2019050522 2019.03.08
- International Application: PCT/EP2019/069597 2019.07.19
- International Announcement: WO2020/016445A 2020.01.23
- Date entered country: 2021-01-19
- Main IPC: A61K35/74
- IPC: A61K35/74 ; A61K35/38
Abstract:
The invention relates to the use of fecal microbiota transplant for preventing and/or reducing systemic and gut treatment-induced inflammation in an individual in need thereof.
Public/Granted literature
- US20210299188A1 FECAL MICROBIOTA COMPOSITION FOR USE IN REDUCING TREATMENT-INDUCED INFLAMMATION Public/Granted day:2021-09-30
Information query
